MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584179 | Name: Adentri

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Adentri, also known as BG-9719 and CVT-124, is a novel adenosine A1 receptor antagonist with unique diuretic activity.

Chemical Structure

Adentri
CAS#166374-48-7

Theoretical Analysis

MedKoo Cat#: 584179

Name: Adentri

CAS#: 166374-48-7

Chemical Formula: C18H24N4O3

Exact Mass: 344.1848

Molecular Weight: 344.42

Elemental Analysis: C, 62.77; H, 7.02; N, 16.27; O, 13.94

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BG 9719; BG-9719; BG9719; CVT 124; CVT-124; CVT124; Adentri.
IUPAC/Chemical Name
1H-Purine-2,6-dione, 3,7-dihydro-8-(1S,2R,4S,5S,6R)-3-oxatricyclo(3.2.1.02,4)oct-6-yl-1,3-dipropyl-
InChi Key
OQCJPFYWFGUHIN-VGYDOTAVSA-N
InChi Code
InChI=1S/C18H24N4O3/c1-3-5-21-16-12(17(23)22(6-4-2)18(21)24)19-15(20-16)11-8-9-7-10(11)14-13(9)25-14/h9-11,13-14H,3-8H2,1-2H3,(H,19,20)/t9-,10+,11-,13-,14+/m1/s1
SMILES Code
O=C(N1CCC)N(CCC)C2=C(NC([C@H]3[C@@]4([H])[C@]5([H])O[C@]5([H])[C@@](C4)([H])C3)=N2)C1=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 344.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Gellai M, Schreiner GF, Ruffolo RR Jr, Fletcher T, DeWolf R, Brooks DP. CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity. J Pharmacol Exp Ther. 1998 Sep;286(3):1191-6. PubMed PMID: 9732378. 2: Herr RJ, Vogt PF, Meckler H, Trova MP, Schow SR, Petter RC. Preparation of 8-substituted xanthine CVT-124 precursor by late stage pyrimidine ring closure. J Org Chem. 2002 Jan 11;67(1):188-93. PubMed PMID: 11777458. 3: Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002 Mar 19;105(11):1348-53. Erratum in: Circulation 2002 Sep 24;106(13):1743. PubMed PMID: 11901047. 4: Gottlieb SS, Skettino SL, Wolff A, Beckman E, Fisher ML, Freudenberger R, Gladwell T, Marshall J, Cines M, Bennett D, Liittschwager EB. Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol. 2000 Jan;35(1):56-9. PubMed PMID: 10636259. 5: Wilcox CS, Welch WJ, Schreiner GF, Belardinelli L. Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J Am Soc Nephrol. 1999 Apr;10(4):714-20. PubMed PMID: 10203354. 6: Oberbauer R, Schreiner GF, Meyer TW. Natriuretic effect of adenosine A1-receptor blockade in rats. Nephrol Dial Transplant. 1998 Apr;13(4):900-3. PubMed PMID: 9568847. 7: Jackson EK, Kost CK Jr, Herzer WA, Smits GJ, Tofovic SP. A(1) receptor blockade induces natriuresis with a favorable renal hemodynamic profile in SHHF/Mcc-fa(cp) rats chronically treated with salt and furosemide. J Pharmacol Exp Ther. 2001 Dec;299(3):978-87. PubMed PMID: 11714886. 8: Pfister JR, Belardinelli L, Lee G, Lum RT, Milner P, Stanley WC, Linden J, Baker SP, Schreiner G. Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine. J Med Chem. 1997 Jun 6;40(12):1773-8. PubMed PMID: 9191953. 9: Gottlieb SS. Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs. 2001;61(10):1387-93. Review. PubMed PMID: 11558828. 10: Gottlieb SS. Adenosine A1 antagonists and the cardiorenal syndrome. Curr Heart Fail Rep. 2008 Jun;5(2):105-9. Review. PubMed PMID: 18765081. 11: Kulick A, Panico C, Gill P, Welch WJ. Low salt intake increases adenosine type 1 receptor expression and function in the rat proximal tubule. Am J Physiol Renal Physiol. 2008 Jul;295(1):F37-41. doi: 10.1152/ajprenal.00061.2008. Epub 2008 May 14. PubMed PMID: 18480183; PubMed Central PMCID: PMC2494514. 12: Vallon V, Miracle C, Thomson S. Adenosine and kidney function: potential implications in patients with heart failure. Eur J Heart Fail. 2008 Feb;10(2):176-87. doi: 10.1016/j.ejheart.2008.01.010. Epub 2008 Feb 1. Review. PubMed PMID: 18242127; PubMed Central PMCID: PMC3151609. 13: Dohadwala MM, Givertz MM. Role of adenosine antagonism in the cardiorenal syndrome. Cardiovasc Ther. 2008 Winter;26(4):276-86. doi: 10.1111/j.1755-5922.2008.00059.x. Review. PubMed PMID: 19035879. 14: Hayes ES. Adenosine receptors and cardiovascular disease: the adenosine-1 receptor (A1) and A1 selective ligands. Cardiovasc Toxicol. 2003;3(1):71-88. Review. PubMed PMID: 12668891. 15: Mader TJ, Menegazzi JJ, Rittenberger JC, Suffoletto BS, Callaway CW, Salcido DD, Logue ES, Sherman LD. The effect of adenosine A1 receptor antagonism on return of spontaneous circulation and short-term survival in prolonged ventricular fibrillation. Prehosp Emerg Care. 2008 Jul-Sep;12(3):352-8. doi: 10.1080/10903120802101223. PubMed PMID: 18584504. 16: Kaplan JL, Gao E, De Garavilla L, Victain M, Minczak B, Dalsey WC. Adenosine A1 antagonism attenuates atropine-resistant hypoxic bradycardia in rats. Acad Emerg Med. 2003 Sep;10(9):923-30. PubMed PMID: 12957973. 17: Belardinelli L, Shryock JC, Zhang Y, Scammells PJ, Olsson R, Dennis D, Milner P, Pfister J, Baker SP. 1,3-Dipropyl-8-[2-(5,6-epoxy)norbornyl]xanthine, a potent, specific and selective A1 adenosine receptor antagonist in the guinea pig heart and brain and in DDT1MF-2 cells. J Pharmacol Exp Ther. 1995 Dec;275(3):1167-76. PubMed PMID: 8531078. 18: Auchampach JA, Jin X, Moore J, Wan TC, Kreckler LM, Ge ZD, Narayanan J, Whalley E, Kiesman W, Ticho B, Smits G, Gross GJ. Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. J Pharmacol Exp Ther. 2004 Mar;308(3):846-56. Epub 2003 Nov 21. PubMed PMID: 14634049. 19: Lucas DG Jr, Hendrick JW, Sample JA, Mukherjee R, Escobar GP, Smits GJ, Crawford FA Jr, Spinale FG. Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure. J Am Coll Surg. 2002 May;194(5):603-9. PubMed PMID: 12022600. 20: Gao E, Kaplan JL, Victain MS, Dalsey WC, de Garavilla L. Adenosine A1 antagonism attenuates beta-adrenergic-resistant sudden hypoxic cardiac insufficiency. Acad Emerg Med. 2005 May;12(5):389-95. PubMed PMID: 15860691.